Showing results (641-650 of 651) with videos related to
Sort By:
Pageof 66
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2025
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO TrialUwe Platzbecker, Lionel Adès, Pau Montesinos, et al.Nature Communications|October 20, 2022
Proteogenomics refines the molecular classification of chronic lymphocytic leukemiaSophie A Herbst, Mattias Vesterlund, Alexander J Helmboldt, et al.Blood Advances|November 6, 2024
Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemiaLeo Ruhnke, Marius Bill, Sven Zukunft, et al.Haematologica|June 9, 2022
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4Sabine Kayser, David Martínez-Cuadrón, Maher Hanoun, et al.Annals of Hematology|January 25, 2023
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group studyDietger Niederwieser, Thomas Lang, Rainer Krahl, et al.Nature Medicine|March 14, 2023
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K Stein-Thoeringer, Neeraj Y Saini, Eli Zamir, et al.Leukemia|July 21, 2025
Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysisJulian Ronnacker, Philippe J Muller, Jan-Henrik Mikesch, et al.Nature Cancer|December 29, 2022
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trialClaudia M Denkinger, Maike Janssen, Ulrike Schäkel, et al.Leukemia|October 28, 2025
Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patientsMarius Bill, Jan-Niklas Eckardt, Konstanze Döhner, et al.Blood|April 14, 2026
Inhibition of high CXCR4 with Motixafortide and absence of single-cell MRD predict outcome after AML consolidationEnise Ceran, Sonia Jaramillo, Anne Kathrin Merbach, et al.Pageof 66